

RECEIVED
CENTRAL FAX CENTER

OCT 19 2005

FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

October 19, 2005

TO: Examiner William Moore
Group 1656
571-272-0933FROM: Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812FAX NO: (571) 273-8300# OF PAGES (incl. cover): 5

Re: U.S. Serial No. 10/809,816, filed March 26, 2004
Entitled "ISOLATED MONKEY CATHEPSIN S PROTEINS, NUCLEIC ACID
MOLECULES ENCODING MONKEY CATHEPSIN S PROTEINS, AND USES
THEREOF"
Atty. Docket No.: CL001507

A Preliminary Amendment (Restriction Election) in the above-identified application
follows. No fee is due for this submission.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

Oct. 19. 2005 9:13AM CELERA GENOMICS

RECEIVED
CENTRAL FAX CENTER

No. 0713 P. 2

OCT 19 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shyr-Jiann LI et al.

Serial No.: 10/809,816

Filed: March 26, 2004

For: ISOLATED MONKEY CATHEPSIN S
PROTEINS, NUCLEIC ACID MOLECULES
ENCODING MONKEY CATHEPSIN S
PROTEINS, AND USES THEREOF

Art Unit: 1656

Examiner: W. Moore

Atty. Docket: CL001507

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

By Facsimile

Sir:

This is in response to an Office Action from Examiner Moore mailed on September 19, 2005 in which a restriction requirement was issued for the above-referenced application.

Applicants hereby elect claim group I, claims 1-2 and 19, directed to polypeptides, etc., for examination and have canceled claims corresponding to the non-elected groups II-X.

Please amend the application as follows: